Bextra Removed From the Market Place
The FDA said recently that it is requiring Pfizer to remove Bextra from the U.S. market. After considering the findings of the FDA Advisory Committee, which met last February, the FDA determined that Bextra's overall risk versus benefit profile is unfavorable. Pfizer will also remove Bextra from European markets.
Studies released as recently as last December show a very high correlation between Bextra use and cardiovascular events such as heart attack and stroke. This risk is especially high in those that use the drug after having coronary artery by-pass surgery. Bextra is also strongly linked with a rare but deadly skin disorder called Stevens-Johnson's Syndrome.
We are encouraged that the FDA took this step to protect U.S. citizens. Hopefully this is a step towards the FDA reclaiming its position as a regulatory body committed to ensuring safe drugs on the market.
If you or a loved one experienced a heart attack, stroke, or serious blood clot while on Bextra, please contact an attorney immediately to discuss your legal rights.